X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs FULFORD INDIA - Comparison Results

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES FULFORD INDIA ALKEM LABORATORIES/
FULFORD INDIA
 
P/E (TTM) x - 398.8 - View Chart
P/BV x 6.1 6.2 98.4% View Chart
Dividend Yield % 0.7 0.1 837.4%  

Financials

 ALKEM LABORATORIES   FULFORD INDIA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
FULFORD INDIA
Mar-14
ALKEM LABORATORIES/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs1,589942 168.7%   
Low Rs1,232450 273.8%   
Sales per share (Unadj.) Rs417.5691.4 60.4%  
Earnings per share (Unadj.) Rs56.311.5 491.2%  
Cash flow per share (Unadj.) Rs64.715.4 421.3%  
Dividends per share (Unadj.) Rs12.702.00 635.0%  
Dividend yield (eoy) %0.90.3 313.3%  
Book value per share (Unadj.) Rs292.9380.0 77.1%  
Shares outstanding (eoy) m119.573.90 3,065.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.0 335.6%   
Avg P/E ratio x25.160.7 41.3%  
P/CF ratio (eoy) x21.845.3 48.1%  
Price / Book Value ratio x4.81.8 262.9%  
Dividend payout %22.617.4 129.3%   
Avg Mkt Cap Rs m168,6532,714 6,213.3%   
No. of employees `000NA0.4 0.0%   
Total wages/salary Rs m9,171505 1,816.1%   
Avg. sales/employee Rs ThNM6,073.0-  
Avg. wages/employee Rs ThNM1,137.4-  
Avg. net profit/employee Rs ThNM100.7-  
INCOME DATA
Net Sales Rs m49,9152,696 1,851.2%  
Other income Rs m1,645125 1,311.9%   
Total revenues Rs m51,5612,822 1,827.2%   
Gross profit Rs m8,482-46 -18,280.8%  
Depreciation Rs m1,00615 6,617.1%   
Interest Rs m67110 7,058.9%   
Profit before tax Rs m8,45154 15,563.5%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,60610 16,729.2%   
Profit after tax Rs m6,73145 15,058.6%  
Gross profit margin %17.0-1.7 -987.5%  
Effective tax rate %19.017.7 107.5%   
Net profit margin %13.51.7 813.5%  
BALANCE SHEET DATA
Current assets Rs m27,0621,738 1,556.8%   
Current liabilities Rs m15,324545 2,813.2%   
Net working cap to sales %23.544.3 53.1%  
Current ratio x1.83.2 55.3%  
Inventory Days Days6748 137.2%  
Debtors Days Days414 958.9%  
Net fixed assets Rs m12,61012 105,962.2%   
Share capital Rs m23939 613.1%   
"Free" reserves Rs m34,4901,443 2,390.1%   
Net worth Rs m35,0271,482 2,363.5%   
Long term debt Rs m1,2120-   
Total assets Rs m54,3872,077 2,618.9%  
Interest coverage x13.66.7 202.5%   
Debt to equity ratio x00-  
Sales to assets ratio x0.91.3 70.7%   
Return on assets %13.62.6 521.5%  
Return on equity %19.23.0 637.1%  
Return on capital %24.94.3 577.4%  
Exports to sales %12.90-   
Imports to sales %3.124.5 12.6%   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540659 233.6%   
Fx inflow Rs m6,56317 38,158.7%   
Fx outflow Rs m3,012673 447.4%   
Net fx Rs m3,552-656 -541.4%   
CASH FLOW
From Operations Rs m7,25990 8,065.0%  
From Investments Rs m1,864105 1,782.2%  
From Financial Activity Rs m-9,273-14 65,763.8%  
Net Cashflow Rs m-150181 -83.1%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 33.1 3.8 871.1%  
FIIs % 0.0 0.1 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 21.2 -  
Shareholders   68,381 4,783 1,429.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  DR. DATSONS LABS  AJANTA PHARMA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 22, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS